Short- versus long-term dual antiplatelet therapy after drug-eluting stent implantation: An individual patient data pairwise and network meta-analysis

Journal of the American College of Cardiology

Volumn 65, Issue 11, 2015, Pages 1092-1102

  Palmerini, Tullio ^a   Sangiorgi, Diego ^a   Valgimigli, Marco ^b   Biondi Zoccai, Giuseppe ^c,d   Feres, Fausto ^e   Abizaid, Alexandre ^e   Costa, Ricardo A ^e   Hong, Myeong Ki ^f   Kim, Byeong Keuk ^f   Jang, Yangsoo ^f   Kim, Hyo Soo ^g   Park, Kyung Woo ^g   Mariani, Andrea ^a   Della Riva, Diego ^a   Genereux, Philippe ^h   Leon, Martin B ^h   Bhatt, Deepak L ⁱ   Bendetto, Umberto ^j   Rapezzi, Claudio ^a   Stone, Gregg W ^h  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^e Dante Pazzanese Hospital   (Brazil)

^f Yonsei University Health System   (South Korea)

^g Seoul National University Hospital   (South Korea)

^h NewYork Presbyterian Hospital   (United States)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

^j UNIVERSITY OF OXFORD   (United Kingdom)

more..

Author keywords

Adverse cardiac; Bleeding major; Event(s) stent; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; THIENOPYRIDINE DERIVATIVE;

ARTICLE; BARE METAL STENT; BLEEDING; CARDIOVASCULAR RESPONSE; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; DRUG WITHDRAWAL; HEART DEATH; HEART INFARCTION; HUMAN; META ANALYSIS (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT COURSE THERAPY; STENT THROMBOSIS; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; DRUG ADMINISTRATION; GRAFT OCCLUSION, VASCULAR; META ANALYSIS; MORTALITY; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION;

DRUG ADMINISTRATION SCHEDULE; DRUG-ELUTING STENTS; GRAFT OCCLUSION, VASCULAR; HUMANS; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84926317811     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2014.12.046     Document Type: Article

References (30)

1. E. Camenzind, P.G. Steg, and W. Wijns Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern Circulation 115 2007 1440 1455
2. G.W. Stone, J.W. Moses, and S.G. Ellis Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents N Engl J Med 356 2007 998 1008
3. F. Otsuka, M. Vorpahl, and M. Nakano Pathology of second-generation everolimus-eluting stents versus first-generation sirolimus- and paclitaxel-eluting stents in humans Circulation 129 2014 211 223
4. R. Virmani, G. Guagliumi, and A. Farb Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 109 2004 701 705
5. E.L. Eisenstein, K.J. Anstrom, and D.F. Kong Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation JAMA 297 2007 159 168
6. M. Pfisterer, H.P. Brunner-La Rocca, and P.T. Buser Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents J Am Coll Cardiol 48 2006 2584 2591
7. G.N. Levine, E.R. Bates, and J.C. Blankenship 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions J Am Coll Cardiol 58 2011 e44 e122
8. S. Yusuf, F. Zhao, S.R. Mehta, S. Chrolavicius, G. Tognoni, and K.K. Fox Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N Engl J Med 345 2001 494 502
9. J.W. van Werkum, A.A. Heestermans, and A.C. Zomer Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry J Am Coll Cardiol 53 2009 1399 1409
10. T. Kimura, T. Morimoto, and Y. Nakagawa Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation Circulation 119 2009 987 995
11. T. Tada, M. Natsuaki, and T. Morimoto Duration of dual antiplatelet therapy and long-term clinical outcome after coronary drug-eluting stent implantation: landmark analyses from the CREDO-Kyoto PCI/CABG Registry Cohort-2 Circ Cardiovasc Interv 5 2012 381 391
12. F. Feres, R.A. Costa, and A. Abizaid Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial JAMA 310 2013 2510 2522
13. H.C. Gwon, J.Y. Hahn, and K.W. Park Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study Circulation 125 2012 505 513
14. B.K. Kim, M.K. Hong, and D.H. Shin A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation) J Am Coll Cardiol 60 2012 1340 1348
15. S.J. Park, D.W. Park, and Y.H. Kim Duration of dual antiplatelet therapy after implantation of drug-eluting stents N Engl J Med 362 2010 1374 1382
16. M. Valgimigli, G. Campo, and M. Monti Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial Circulation 125 2012 2015 2026
17. F. Song, I. Harvey, and R. Lilford Adjusted indirect comparison may be less biased than direct comparison for evaluating new pharmaceutical interventions J Clin Epidemiol 61 2008 455 463
18. D.E. Cutlip, S. Windecker, and R. Mehran Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351
19. A. Liberati, D.G. Altman, and J. Tetzlaff The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration BMJ 339 2009 b2700
20. J.W. Eikelboom, S.R. Mehta, S.S. Anand, C. Xie, K.A. Fox, and S. Yusuf Adverse impact of bleeding on prognosis in patients with acute coronary syndromes Circulation 114 2006 774 782
21. S.V. Manoukian, F. Feit, and R. Mehran Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial J Am Coll Cardiol 49 2007 1362 1368
22. G. Ndrepepa, P.B. Berger, and J. Mehilli Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point J Am Coll Cardiol 51 2008 690 697
23. L. Mauri, D.J. Kereiakes, and R.W. Yeh Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents N Engl J Med 371 2014 2155 2166
24. J. Daemen, P. Wenaweser, and K. Tsuchida Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study Lancet 369 2007 667 678
25. M. Gilard, P. Barragan, and A. Noryani 6- versus 24-month dual antiplatelet therapy after implantation of drug eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial J Am Coll Cardiol 65 2015 777 786
26. Schulz-Schüpke S, Mehilli J, Laugwitz K-L, et al. Randomized, double-blind trial of 6 versus 12 months of dual antiplatelet therapy after DES implantation (ISAR-SAFE). Presented at: American Heart Association Scientific Sessions; November 16, 2014; Chicago, IL.
27. S. Cassese, R.A. Byrne, T. Tada, L.A. King, and A. Kastrati Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials Eur Heart J 33 2012 3078 3087
28. G. El-Hayek, F. Messerli, and S. Bangalore Meta-analysis of randomized clinical trials comparing short-term versus long-term dual antiplatelet therapy following drug-eluting stents Am J Cardiol 114 2014 236 242
29. M. Valgimigli, S.J. Park, and H.S. Kim Benefits and risks of long-term duration of dual antiplatelet therapy after drug-eluting stenting: a meta-analysis of randomized trials Int J Cardiol 168 2013 2579 2587
30. M. Valgimigli, M. Borghesi, M. Tebaldi, P. Vranckx, G. Parrinello, and R. Ferrari Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY) Eur Heart J 34 2013 909 919